Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Gains from Sales and Divestitures (2023 - 2024)

Historic Gains from Sales and Divestitures for Standard Biotools (LAB) over the last 2 years, with Q4 2024 value amounting to $5.3 million.

  • Standard Biotools' Gains from Sales and Divestitures rose 7952.86% to $5.3 million in Q4 2024 from the same period last year, while for Dec 2024 it was $5.3 million, marking a year-over-year increase of 7952.86%. This contributed to the annual value of $5.3 million for FY2024, which is 7952.86% up from last year.
  • Latest data reveals that Standard Biotools reported Gains from Sales and Divestitures of $5.3 million as of Q4 2024, which was up 7952.86% from $4.0 million recorded in Q3 2024.
  • Standard Biotools' Gains from Sales and Divestitures' 5-year high stood at $5.3 million during Q4 2024, with a 5-year trough of $1.7 million in Q1 2024.